CSTL
Castle Biosciences, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.55
P/S
2.15
EV/EBITDA
50.15
DCF Value
$-187.23
FCF Yield
3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.7%
Operating Margin
-12.4%
Net Margin
-7.0%
ROE
-5.3%
ROA
-5.0%
ROIC
-6.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $87.0M | $-2.3M | $-0.08 |
| FY 2025 | $344.2M | $-24.2M | $-0.83 |
| Q3 2025 | $83.0M | $-501.0K | $-0.02 |
| Q2 2025 | $86.2M | $4.5M | $0.15 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.19
Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma and myPath Melanoma, a proprietary GEP test to diagnose suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.